The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.
The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.
But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.
Umberto Galderisi from the University of Naples and president of Stem Cell Italy, is among critics of the bill.
He said the clinical trials would "never have been allowed" if scientific accepted practice had been followed.
"This is legislating on the basis of public opinion. It means exploiting suffering. Patients are not lab rats," he told AFP, adding there were "no scientific certainties" the therapy could work.
Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.
At one demonstration, protesters wore T-shirts with the slogan: "Yes to Stamina, Yes to Life".
The association Stem Cell Research Italy has branded the new law as "unacceptable" saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.
US journal Nature said it was a "rogue" therapy.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
